Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

被引:3
作者
Kuwabara, Chihiro [1 ]
Sakuma, Yukie [2 ]
Kume, Ayaka [1 ]
Tamura, Yuri [1 ]
Shimizu, Ryo [1 ]
Iwai, Rie [3 ]
Ishii, Akihiro [3 ]
Tanaka, Hiroaki [1 ]
机构
[1] Asahi Gen Hosp, Dept Hematol, I-1326, Asahi, Chiba 2892511, Japan
[2] Asahi Gen HoIspital, Clin Res Support Ctr, Asahi, Chiba, Japan
[3] Asahi Gen Hosp, Dept Transfus Med, Asahi, Chiba, Japan
关键词
Non-IgM monoclonal gammopathy; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Immunoparesis; Female; MULTIPLE-MYELOMA; RISK; PROGRESSION;
D O I
10.1007/s12185-018-2555-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-immunoglobulin (Ig)-M monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion with the potential to evolve into a malignant plasma cell neoplasm. The prevalence of MGUS differs by ethnicity and is lower in the Japanese population than in the Western population. However, there is limited evidence about the clinical course of MGUS in Asian races. The present study aims at elucidating the clinical course and prognosis of Japanese patients with non-IgM MGUS in the clinical setting. We retrospectively examined 1009 patients with non-IgM MGUS identified by screening procedures. The median overall survival of these patients was >20years, and only one-fifth patients died of plasma cell neoplasms. The cumulative incidence of plasma cell neoplasms requiring treatment was 19%. Multivariate analysis revealed that immunoparesis and female gender were independent factors affecting treatment requirement. Although the characteristics and clinical course of patients with non-IgM MGUS obtained in this study were found to be essentially similar to those of previous studies, we report here for the first time that female gender is a significant independent factor for requiring treatment.
引用
收藏
页码:154 / 161
页数:8
相关论文
共 19 条
  • [1] Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
    Hillengass, Jens
    Fechtner, Kerstin
    Weber, Marc-Andre
    Baeuerle, Tobias
    Ayyaz, Sofia
    Heiss, Christiane
    Hielscher, Thomas
    Moehler, Thomas M.
    Egerer, Gerlinde
    Neben, Kai
    Ho, Anthony D.
    Kauczor, Hans-Ulrich
    Delorme, Stefan
    Goldschmidt, Hartmut
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1606 - 1610
  • [2] Mechanisms of action and resistance for multiple myeloma novel drug treatments
    Iida, Shinsuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (03) : 271 - 272
  • [3] Prevalence of monoclonal gammopathy of undetermined significance: Study of 52,802 persons in Nagasaki city, Japan
    Iwanaga, Masako
    Tagawa, Masuko
    Tsukasaki, Kunihiro
    Kamihira, Shimera
    Tomonaga, Masao
    [J]. MAYO CLINIC PROCEEDINGS, 2007, 82 (12) : 1474 - 1479
  • [4] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    Kanda, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
  • [5] SCREENING FOR MULTIPLE-MYELOMA USING ROUTINE LABORATORY TEST-RESULTS
    KITAMURA, M
    YAMAGUCHI, H
    MURAKAWA, K
    MURAO, T
    IIZUKA, Y
    [J]. CLINICAL BIOCHEMISTRY, 1982, 15 (01) : 17 - 21
  • [6] Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study
    Kristinsson, Sigurdur Y.
    Tang, Min
    Pfeiffer, Ruth M.
    Bjorkholm, Magnus
    Blimark, Cecilie
    Mellqvist, Ulf-Henrik
    Wahlin, Anders
    Turesson, Ingemar
    Landgren, Ola
    [J]. BLOOD, 2010, 116 (15) : 2651 - 2655
  • [7] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569
  • [8] Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
    Landgren, O
    Gridley, G
    Turesson, I
    Caporaso, NE
    Goldin, LR
    Baris, D
    Fears, TR
    Hoover, RN
    Linet, MS
    [J]. BLOOD, 2006, 107 (03) : 904 - 906
  • [9] Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
    Larsen, J. T.
    Kumar, S. K.
    Dispenzieri, A.
    Kyle, R. A.
    Katzmann, J. A.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2013, 27 (04) : 941 - 946
  • [10] Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
    Mateos, Maria-Victoria
    Hernandez, Miguel-Teodoro
    Giraldo, Pilar
    de la Rubia, Javier
    de Arriba, Felipe
    Lopez Corral, Lucia
    Rosinol, Laura
    Paiva, Bruno
    Palomera, Luis
    Bargay, Joan
    Oriol, Albert
    Prosper, Felipe
    Lopez, Javier
    Olavarria, Eduardo
    Quintana, Nuria
    Garcia, Jose-Luis
    Blade, Joan
    Lahuerta, Juan-Jose
    San Miguel, Jesus-F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (05) : 438 - 447